| ［1］ |
Ingram JR, Jenkins⁃Jones S, Knipe DW, et al. Population⁃based clinical practice research datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa［J］. Br J Dermatol, 2018,178（4）:917⁃924. doi: 10.1111/bjd.16101.
|
| ［2］ |
Kirsten N, Zander N, Augustin M. Prevalence and cutaneous comorbidities of hidradenitis suppurativa in the German working population［J］. Arch Dermatol Res, 2021,313（2）:95⁃99. doi: 10. 1007/s00403⁃020⁃02065⁃2.
|
| ［3］ |
Sandhu VK, Shah M, Piguet V, et al. The impact of hidradenitis suppurativa on work productivity and activity impairment［J］. Br J Dermatol, 2020,182（5）:1288⁃1290. doi: 10.1111/bjd.18695.
|
| ［4］ |
中国反常性痤疮/化脓性汗腺炎诊疗专家共识制订小组. 中国反常性痤疮/化脓性汗腺炎诊疗专家共识（2021版）［J］. 中华皮肤科杂志, 2021,54（2）:97⁃104. doi: 10.35541/cjd.20200802.
|
| ［5］ |
Kimball AB, Tzellos T, Calimlim BM, et al. Achieving hidradenitis suppurativa response score is associated with significant improvement in clinical and patient⁃reported outcomes: post hoc analysis of pooled data from PIONEER I and II［J］. Acta Derm Venereol, 2018,98（10）:932⁃937. doi: 10.2340/00015555⁃3012.
|
| ［6］ |
Hessam S, Scholl L, Sand M, et al. A novel severity assessment scoring system for hidradenitis suppurativa［J］. JAMA Dermatol, 2018,154（3）:330⁃335. doi: 10.1001/jamadermatol.2017.5890.
|
| ［7］ |
Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa［J］. N Engl J Med, 2016,375（5）:422⁃434. doi: 10.1056/NEJMoa1504370.
|
| ［8］ |
Zouboulis CC, Okun MM, Prens EP, et al. Long⁃term adalimumab efficacy in patients with moderate⁃to⁃severe hidradenitis suppurativa/acne inversa: 3⁃year results of a phase 3 open⁃label extension study［J］. J Am Acad Dermatol, 2019,80（1）:60⁃69. doi: 10.1016/j.jaad.2018.05.040.
|
| ［9］ |
Caposiena Caro RD, Cannizzaro MV, Tartaglia C, et al. Clinical response rate and flares of hidradenitis suppurativa in the treatment with adalimumab［J］. Clin Exp Dermatol, 2020,45（4）:438⁃444. doi: 10.1111/ced.14127.
|
| ［10］ |
Salvador⁃Rodriguez L, Montero⁃Vílchez T, Arias⁃Santiago S, et al. Paradoxical hidradenitis suppurativa in patients receiving TNF⁃α inhibitors: case series, systematic review, and case meta⁃analysis［J］. Dermatology, 2020,236（4）:307⁃313. doi: 10.1159/000506074.
|
| ［11］ |
Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double⁃blind, placebo⁃controlled crossover trial［J］. J Am Acad Dermatol, 2010,62（2）:205⁃217. doi: 10.1016/j.jaad. 2009.06.050.
|
| ［12］ |
Mekkes JR, Bos JD. Long⁃term efficacy of a single course of infliximab in hidradenitis suppurativa［J］. Br J Dermatol, 2008,158（2）:370⁃374. doi: 10.1111/j.1365⁃2133.2007.08332.x.
|
| ［13］ |
Paradela S, Rodríguez⁃Lojo R, Fernández⁃Torres R, et al. Long⁃term efficacy of infliximab in hidradenitis suppurativa［J］. J Dermatolog Treat, 2012,23（4）:278⁃283. doi: 10.3109/09546634. 2012.683767.
|
| ［14］ |
Brunasso AM, Massone C. Treatment of hidradenitis suppurativa with tumour necrosis factor⁃alpha inhibitors: an update on infliximab［J］. Acta Derm Venereol, 2011,91（1）:70⁃71. doi: 10.2340/00015555⁃0989.
|
| ［15］ |
Oskardmay AN, Miles JA, Sayed CJ. Determining the optimal dose of infliximab for treatment of hidradenitis suppurativa［J］. J Am Acad Dermatol, 2019,81（3）:702⁃708. doi: 10.1016/j.jaad. 2019.05.022.
|
| ［16］ |
Vural S, Gündoğdu M, Akay BN, et al. Hidradenitis suppurativa: clinical characteristics and determinants of treatment efficacy［J］. Dermatol Ther, 2019,32（5）:e13003. doi: 10.1111/dth.13003.
|
| ［17］ |
Giamarellos⁃Bourboulis EJ, Pelekanou E, Antonopoulou A, et al. An open⁃label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa［J］. Br J Dermatol, 2008,158（3）:567⁃572. doi: 10.1111/j.1365⁃2133.2007. 08372.x.
|
| ［18］ |
Cusack C, Buckley C. Etanercept: effective in the management of hidradenitis suppurativa［J］. Br J Dermatol, 2006,154（4）:726⁃729. doi: 10.1111/j.1365⁃2133.2005.07067.x.
|
| ［19］ |
Blok JL, Li K, Brodmerkel C, et al. Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum［J］. Br J Dermatol, 2016,174（4）:839⁃846. doi: 10. 1111/bjd.14338.
|
| ［20］ |
Kovacs M, Podda M. Guselkumab in the treatment of severe hidradenitis suppurativa［J］. J Eur Acad Dermatol Venereol, 2019,33（3）:e140⁃140e141. doi: 10.1111/jdv.15368.
|
| ［21］ |
Montero⁃Vilchez T, Martinez⁃Lopez A, Salvador⁃Rodriguez L, et al. The use of guselkumab 100 mg every 4 weeks on patients with hidradenitis suppurativa and a literature review［J］. Dermatol Ther, 2020,33（3）:e13456. doi: 10.1111/dth.13456.
|
| ［22］ |
Leslie KS, Tripathi SV, Nguyen TV, et al. An open⁃label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa［J］. J Am Acad Dermatol, 2014,70（2）:243⁃251. doi: 10.1016/j.jaad.2013.09.044.
|
| ［23］ |
Tzanetakou V, Kanni T, Giatrakou S, et al. Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial［J］. JAMA Dermatol, 2016,152（1）:52⁃59. doi: 10. 1001/jamadermatol.2015.3903.
|
| ［24］ |
André R, Marescassier H, Gabay C, et al. Long⁃term therapy with anakinra in hidradenitis suppurativa in three patients［J］. Int J Dermatol, 2019,58（11）:e208⁃e209. doi: 10.1111/ijd.14596.
|
| ［25］ |
Prussick L, Rothstein B, Joshipura D, et al. Open⁃label, investigator⁃initiated, single⁃site exploratory trial evaluating secukinumab, an anti⁃interleukin⁃17A monoclonal antibody, for patients with moderate⁃to⁃severe hidradenitis suppurativa［J］. Br J Dermatol, 2019,181（3）:609⁃611. doi: 10.1111/bjd.17822.
|
| ［26］ |
Thorlacius L, Theut Riis P, Jemec G. Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report［J］. Br J Dermatol, 2018,179（1）:182⁃185. doi: 10.1111/bjd.15769.
|
| ［27］ |
Schuch A, Fischer T, Boehner A, et al. Successful treatment of severe recalcitrant hidradenitis suppurativa with the interleukin⁃17a antibody secukinumab［J］. Acta Derm Venereol, 2018,98（1）:151⁃152. doi: 10.2340/00015555⁃2794.
|
| ［28］ |
Giamarellos⁃Bourboulis E, Argyropoulou M, Kanni T, et al. Efficacy and safety of IFX⁃1, an anti⁃C5a monoclonal antibody in an open label Phase 2a study in patients with severe hidradenitis suppurativa （HS） not eligible for adalimumab［R］// Special Issue: Abstracts of the 7th European Hidradenitis Suppurativa Foundation （EHSF） Congress, Rotterdam, The Netherlands. Exp Dermatol, 2018,27（S1）: 5⁃32.doi: 10.1111/exd.13538.
|
